- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Phase 3 Trial
Recent news which mentions Phase 3 Trial
Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study
December 21, 2021
Tickers
ALDX
From Benzinga
Summit Therapeutics' Infection Candidate Flunks In Head-To-Head Trial
December 20, 2021
Tickers
SMMT
From Benzinga
Pfizer Submits Application For Approval Of COVID-19 Shot For Adolescents Aged 12 To 15
December 17, 2021
From Benzinga
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
December 17, 2021
From Benzinga
FDA's Office Agrees On 12-Month Reduction In Pain As Primary Endpoint For Mesoblast's Back Pain Study
December 16, 2021
Tickers
MESO
From Benzinga
Valneva's COVID-19 Vaccine Booster Works As A Follow-Up To Its Own Shot
December 16, 2021
Tickers
VALN
From Benzinga
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
December 15, 2021
From Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
December 15, 2021
From Benzinga
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
December 14, 2021
From Benzinga
Cidara Therapeutics Stock Slides Despite Acing Rezafungin Trial In Fungal Infection
December 14, 2021
Tickers
CDTX
From Benzinga
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
December 14, 2021
Tickers
SNY
From Benzinga
Final Data Reaffirms Efficacy Of Pfizer's COVID-19 Antiviral Treatment
December 14, 2021
Tickers
PFE
From Benzinga
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
December 13, 2021
Tickers
JAZZ
From Benzinga
CSL Behring, UniQure's Hemophilia B Gene Therapy Hits Primary Endpoint
December 09, 2021
Tickers
QURE
From Benzinga
Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients
December 09, 2021
From Benzinga
Why Are Intercept Pharmaceuticals Shares Falling Today?
December 09, 2021
Tickers
ICPT
From Benzinga
Aurinia's Voclosporin Shows favorable Risk/Benefit Profile Over 3 Years In Lupus Nephritis
December 09, 2021
Tickers
AUPH
From Benzinga
Novartis' New Kisqali Data Shows Consistent Overall Survival Benefit Across Metastatic Breast Cancer Settings
December 08, 2021
Tickers
NVS
From Benzinga
Radius Health Reveals Detailed Elacestrant Data From Late-Stage Breast Cancer Trial
December 08, 2021
Tickers
RDUS
From Benzinga
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement
December 08, 2021
Tickers
NBIX
From Benzinga
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022
December 07, 2021
From Benzinga
Medicago, GSK's Plant-Based COVID-19 Vaccine Candidate Hits 75% Efficacy Against Delta Strain
December 07, 2021
Tickers
GSK
From Benzinga
Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study
December 07, 2021
Tickers
ACAD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.